Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Thomas S, Marshall"'
Autor:
Kavita Sail, Pablo Martinez-Martin, Thomas S. Marshall, Dendy Macaulay, Fan Mu, Yash J. Jalundhwala, Erika Ohashi
Publikováno v:
Movement Disorders
Repisalud
Instituto de Salud Carlos III (ISCIII)
Repisalud
Instituto de Salud Carlos III (ISCIII)
Parkinson's disease is a progressive, disabling neurodegenerative disorder associated with significant economic burden for patients and caregivers. The objective of this study was to compare the direct and indirect economic burden of Parkinson's pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::248ee11903fb0cd5145f9308460e8ca6
http://europepmc.org/articles/PMC6590233
http://europepmc.org/articles/PMC6590233
Autor:
Jeffrey Sullivan, Tiffany Shih, Cindy Zadikoff, Jennifer Benner, Emma van Eijndhoven, Thomas S. Marshall, Yash J. Jalundhwala, Darius N. Lakdawalla, Kavita R. Sail
Publikováno v:
Forum for health economicspolicyReferences. 23(2)
Objectives Quantify the value of functional status (FS) improvements consistent in magnitude with improvements due to levodopa-carbidopa intestinal gel (LCIG) treatment, among the advanced Parkinson’s disease (APD) population. Methods The Health Ec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::594f52da060c45971fb4e1020b946518
https://pubmed.ncbi.nlm.nih.gov/33984886
https://pubmed.ncbi.nlm.nih.gov/33984886
Autor:
Leah S. Kleinman, A. Jon Stoessl, Thomas S. Marshall, Kavita R. Sail, Angelo Antonini, Per Odin, Anne Skalicky, Koray Onuk
Publikováno v:
Current Medical Research and Opinion. 34:2063-2073
Lack of a global consensus on the definition of advanced Parkinson's disease (APD) and considerations for timing of device-aided therapies may result in heterogeneity in care.To reach consensus among movement disorder specialists regarding key patien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d73fc5985abd5d71b7be4fb79d7b663
https://doi.org/10.1080/03007995.2018.1502165
https://doi.org/10.1080/03007995.2018.1502165
Publikováno v:
Value in Health. 20:1383-1393
Background Effective treatment for advanced Parkinson disease (PD) uncontrolled with oral medication includes device-aided therapies such as deep brain stimulation (DBS) and continuous levodopa-carbidopa infusion to the duodenum via a portable pump.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25f968642cd6a815d4331e3aed60eb2b
https://doi.org/10.1016/j.jval.2017.06.001
https://doi.org/10.1016/j.jval.2017.06.001
Autor:
Thomas S. Marshall, Rakhi Baj, Julia Lowin, Henrietta Konwea, Kavita Sail, Yash J. Jalundhwala, K R Chaudhuri
Publikováno v:
Journal of Medical Economics. 20:1207-1215
Parkinson's disease (PD) is an incurable, progressive neurological condition, with symptoms impacting movement, walking, and posture that eventually become severely disabling. Advanced PD (aPD) has a significant impact on quality-of-life (QoL) for pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62833ec753b0ecd8baea79211263ad72
https://doi.org/10.1080/13696998.2017.1379411
https://doi.org/10.1080/13696998.2017.1379411
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
Jack Burks,1 Thomas S Marshall,2 Xiaolan Ye2 1Nova Southeastern University, Davie, FL, 2AbbVie Inc, Chicago, IL, USA Purpose: To evaluate adherence to disease-modifying therapies (DMTs) among patients with multiple sclerosis (MS) initiating oral and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32afea6d0a6c3dd80722e8045ca3a27a
https://doi.org/10.2147/ceor.s130334
https://doi.org/10.2147/ceor.s130334
Autor:
Thomas S. Marshall, Kavita Sail, Emma van Eijndhoven, Jeffrey Sullivan, Tiffany Shih, Darius N. Lakdawalla, Cindy Zadikoff, Yash J. Jalundhwala
Aims: To estimate the relationship between functional status (FS) impairment and nursing home admission (NHA) risk in Parkinson’s disease (PD) patients, and quantify the effect of advanced PD (APD) treatment on NHA risk relative to standard of care
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e96f85a6f1cedf7dbc71cbdce6af849
Publikováno v:
Clinical Drug Investigation. 35:229-238
Background and Objective Chronic kidney disease (CKD) is a highly morbid disorder. The most severe form of CKD is end-stage renal disease (ESRD), in which the patient requires some form of renal replacement therapy to survive. The increasing incidenc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b3fadb04672a7476b13f1c28ded7c2e8
https://doi.org/10.1007/s40261-014-0264-4
https://doi.org/10.1007/s40261-014-0264-4
Autor:
Beenish S Manzoor, George A. Follows, Paul M. Barr, Maryam Sarraf Yazdy, Irina Pivneva, Daniel Dingfeng Jiang, Chaitra S. Ujjani, Bruce D. Cheson, Anthony R. Mato, Toby A. Eyre, Mazyar Shadman, Jennifer R. Brown, German Pena, Danielle M. Brander, Jacqueline Nielsen, John N. Allan, Simon Sharmokh, James M. Pauff, Nicole Lamanna, Rajat Bannerji, Lindsey E. Roeker, Thomas S. Marshall, William G. Wierda, Hande H. Tuncer, Barbara Eichhorst, Kavita Sail, Anna Schuh, Brian T. Hill, Alan P Skarbnik, Stephen J. Schuster
Publikováno v:
Blood. 134:1756-1756
BACKGROUND Novel agents have changed the treatment landscape in chronic lymphocytic leukemia (CLL), however little has been reported about real-world treatment sequence patterns and associated outcomes post-introduction of novel agents. Studies have
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee18ffdd02a6fba2881893dabad29ed6
https://doi.org/10.1182/blood-2019-124600
https://doi.org/10.1182/blood-2019-124600
Autor:
Nicole Lamanna, Anna Schuh, Bruce D. Cheson, Chaitra S. Ujjani, George A. Follows, James M. Pauff, Paul M. Barr, Annie Guerin, Nnadozie Emechebe, Jennifer R. Brown, Toby A. Eyre, Rajat Bannerji, Rajesh Kamalakar, Daniel Dingfeng Jiang, John N. Allan, Simon Sharmokh, Jacqueline Nielsen, Anthony R. Mato, Thomas S. Marshall, Hande H. Tuncer, Mazyar Shadman, German Pena, Maryam Sarraf Yazdy, Barbara Eichhorst, William G. Wierda, Kavita Sail, Lindsey E. Roeker, Irina Pivneva, Beenish S Manzoor, Brian T. Hill, Alan P Skarbnik, Stephen J. Schuster, Danielle M. Brander
Publikováno v:
Blood. 134:3048-3048
BACKGROUND The recent approval of novel agents (NAs) has changed the treatment landscape in chronic lymphocytic leukemia (CLL), however, there remains uncertainty regarding treatment discontinuation patterns in real-world (RW) settings. This study as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34e5d24bdc4bcaae1348a0b358dbdea7
https://doi.org/10.1182/blood-2019-131401
https://doi.org/10.1182/blood-2019-131401